A growing body of research is connecting GLP-1 receptor agonists, the class of drugs behind brand names like Ozempic, Wegovy, Mounjaro, and Zepbound, to a serious eye condition that can cause permanent vision loss. The condition has a long medical name: non-arteritic anterior ischemic optic neuropathy, or NAION. Eye specialists sometimes describe it as a stroke of the optic nerve. And once the damage is done, there is currently no treatment that can undo it.

This article is not written to frighten you or push you off your medication without talking to your physician. Millions of people are benefiting from these drugs every day. But the question health experts are now asking out loud is this: when a rare side effect starts appearing in large numbers of people, does it stay rare?

What Are GLP-1 Drugs and Why Are So Many People Taking Them?

GLP-1 stands for glucagon-like peptide-1. These drugs mimic a hormone your gut naturally releases after eating. They slow digestion, reduce hunger, and help control blood sugar. Originally developed for type 2 diabetes, they became household names when studies showed they could also produce significant weight loss.

The popularity of these drugs has been extraordinary. Roughly 15 million people in the United States are currently taking GLP-1 medications, and that number keeps climbing. Many of these users do not have diabetes at all. They are taking the drug specifically to lose weight, often without a full picture of what the long-term risks might look like.

The Eye Condition No One Was Expecting

NAION occurs when blood flow to the front portion of the optic nerve is cut off or severely reduced. The optic nerve is the cable that carries visual signals from your eye to your brain. When that nerve loses its blood supply, even briefly, it can suffer damage that leads to permanent partial or total vision loss in that eye. Health authorities, including the World Health Organization, confirm that this vision loss is usually permanent.

The condition is not brand new. It was already known to affect adults over 50, people with high blood pressure, and people with diabetes. What caught researchers off guard was a cluster of cases appearing in people who had recently started taking semaglutide-based medications.

The alarm was first raised in 2024, when physicians at Massachusetts Eye and Ear, a Harvard Medical School-affiliated hospital, published findings in the journal JAMA Ophthalmology. Their retrospective study of more than 16,000 neuro-ophthalmic patients found that people with type 2 diabetes or obesity who were taking semaglutide had a significantly higher rate of NAION compared to those taking other medications. Among diabetes patients in the study, semaglutide users showed a hazard ratio of 4.28, meaning the risk of developing NAION was more than four times higher than in comparable patients on other glucose-lowering drugs.

A separate Danish and Norwegian study that same year, drawing on data from more than 424,000 patients with type 2 diabetes, found that once-weekly semaglutide use more than doubled the five-year risk of NAION compared to patients taking other diabetes medications.

A Small Percentage Times Millions of People

Here is where the math matters. NAION is classified as “very rare,” meaning it may affect up to 1 in 10,000 people. The European Medicines Agency, which regulates drugs across 27 countries, formally added this classification in June 2025, recommending that product information for Ozempic, Wegovy, and Rybelsus be updated to include NAION as a side effect. The World Health Organization issued its own safety alert shortly after.

But consider what “very rare” actually means when tens of millions of people are taking a drug. If even 1 in 10,000 semaglutide users develops NAION, and 15 million Americans are using GLP-1 medications, that translates to roughly 1,500 potential cases in the United States alone. And that figure is based on the most conservative estimate.

The American Optometric Association’s clinical guidance report put it bluntly: “There is a low risk of serious ocular side effects. But a low risk of a big number is a big risk.”

The University at Buffalo researchers who published a related case series in JAMA Ophthalmology noted something else that raised eyebrows. NAION almost always strikes one eye at a time. But some patients on GLP-1 drugs were presenting with the condition in both eyes simultaneously, which is considered atypical and potentially more alarming.

The Research Is Still Sorting Itself Out

To be fair, the picture is not entirely clear-cut. A large February 2025 retrospective study that pooled data from 37 million diabetes patients across 14 international databases found that semaglutide users showed about 14 to 15 NAION cases per 100,000 patients annually, and when compared to other GLP-1 drugs, the risk was not significantly different. This suggests the vision risk may apply to the entire class of GLP-1 medications, not just semaglutide specifically.

A separate large cohort study published in JAMA Network Open, covering 185,000 individuals on GLP-1 drugs, found a slightly higher risk of developing diabetic retinopathy, but a similar rate of NAION compared to those on other treatments. And two studies presented at the American Academy of Ophthalmology’s 2025 annual meeting offered conflicting signals: one tied GLP-1 drugs to increased NAION risk and diabetic retinopathy risk, while another suggested the drugs might actually protect against dry age-related macular degeneration.

Scientists are careful to note that none of the current evidence proves that GLP-1 drugs cause NAION. What exists is a statistically significant association that has now been observed across multiple studies, multiple countries, and multiple drug databases. That is enough to prompt regulatory bodies to act and researchers to dig deeper.

Who May Be at Highest Risk?

Physicians are paying special attention to patients who already have underlying vascular risk factors. High blood pressure, high cholesterol, diabetes, a history of cardiovascular disease, and a structural eye condition called a small optic disc are all considered risk factors for NAION independent of GLP-1 use. When these pre-existing vulnerabilities are combined with a medication that may affect blood flow to the optic nerve, the potential for harm may be higher.

The symptoms to watch for are specific and sudden: vision loss in one eye that seems to come on without warning, often noticed upon waking. There may be a dark or blurry area in part of your field of vision, or a sense that something has been “wiped away” in one corner of sight. There is typically no pain, which is part of why people sometimes wait before seeking care. Any of these symptoms should be treated as a medical emergency.

Where Things Stand Right Now

As of June 2026, the European Medicines Agency has updated its labeling requirements for semaglutide to include NAION. The World Health Organization has issued a formal safety alert. And a multidistrict litigation involving GLP-1 vision loss lawsuits was consolidated in the Eastern District of Pennsylvania in December 2025. Legal analysts report that over 1,800 lawsuits had been filed by mid-2025, with more expected as scientific review continues.

The U.S. Food and Drug Administration has not yet added a NAION warning to American drug labels for semaglutide. Novo Nordisk, which manufactures Ozempic and Wegovy, has not yet updated its U.S. prescribing information to reflect the risk. Public health advocates and some legal experts have called for a black box warning, the FDA’s highest-level alert.

The American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society have both weighed in, stating that they do not recommend that all semaglutide users stop their medication immediately if they develop NAION, since the benefits of the drug may still outweigh individual risks, depending on the patient’s overall health. But both organizations agree that sudden vision changes of any kind require immediate medical evaluation.

What This Means for You

If you are currently taking a GLP-1 medication for weight loss or diabetes management, here are the most important things to keep in mind.

1. Do not stop your medication without talking to your physician. For many people, the health benefits of these drugs are substantial, and an abrupt stop can create its own risks.
2. Tell your physician if you have existing eye problems, high blood pressure, or a history of cardiovascular disease. These factors may influence how closely you should be monitored.
3. Take sudden vision changes seriously. If you wake up one morning and something looks wrong with one eye, that is not something to wait out. Call your physician or go to an emergency room. Time may matter.
4. Ask questions. Ask your physician whether NAION has been discussed in your care plan. Ask whether your specific risk factors warrant more frequent eye exams. You have the right to that conversation

The Larger Question

GLP-1 medications have been genuinely life-changing for many people. They have helped reduce the burden of obesity, lower cardiovascular risk, and control blood sugar in ways that were difficult to achieve before. None of that is in dispute.

But when a drug reaches the scale of tens of millions of users, even rare side effects become a public health question. A risk that affects fewer than 1 in 10,000 people in a clinical trial still produces thousands of real individuals with real and permanent vision loss when multiplied across the population taking these drugs. Those individuals deserve answers, updated labels, and the chance to make informed decisions before the lights go out.

Research is ongoing. Regulatory conversations are happening. In the meantime, staying informed, staying in communication with your physician, and taking any sudden change in vision seriously are the most important steps you can take.

The post The Weight-Loss Drug Nobody Warned You About: When the Scale Goes Down, and Your Sight Goes With It appeared first on Medika Life.

Diabetes

40 million Americans have diabetes mellitus, or 12% of the population. Of these 38 million have type 2 diabetes (previously known as “adult onset”) and 2 million have type 1 (previously known as “juvenile diabetes.) 29 million have been diagnosed, yet 11 million are unaware that they have the disease. Our focus is type 2 diabetes.

Diabetes type 2 incidence increases with age, such that nearly 30% of those over 65 have diabetes, compared to ages of 40 to 59 with a 12% incidence, and 4% for those under 40.

Of great concern is the rising incidence over time. In 2000, a total of 8% of Americans had diabetes. This has risen to about 12% or a 50% increase in just two decades. Some would term this an epidemic. Of further concern, many young people are now developing diabetes.

Diabetes substantially increases the risk of multiple diseases. Among them are blindness, kidney failure (the most common reason for a kidney transplant is diabetes damage), cardiovascular disease, including heart attacks and strokes, loss of sensation in the feet and lower legs (neuropathy and paresthesia), reduced vascular supply to the lower legs and the feet, often resulting in amputation of toes, feet, or legs, and Alzheimer’s disease.

Diabetes and its associated diseases combined cost America $640 billion per year, or 25% of all healthcare spending.

The major risk factors for type two diabetes include being substantially overweight, having a family history, being inactive or sedentary, and being over the age of 45.

You can’t change your family history. But your genes need not be your destiny. The basics of prevention include losing weight, increasing activity, eating healthy foods, and substantially reducing the intake of ultra-processed foods.

Diabetes and Alzheimer’s disease

Type 2 diabetes increases the risk of Alzheimer’s disease by 50 to 65%. It’s a shared risk factor with increased blood pressure and increased cholesterol, all leading to brain cell inflammation.

The increased risk of diabetes correlates with insulin resistance not only throughout the body but also in the brain. Some scientists think that brain insulin resistance is separate from the resistance in other parts of the body, and as a result, use the term “type 3 diabetes” as a synonym for Alzheimer’s disease. The brain cells are in effect “starved” for glucose, which is the neurons’ principal source of energy, despite plenty of glucose circulating in the bloodstream.

Insulin resistance of brain cells is associated with increased oxidative stress and neuroinflammation, which in turn leads to neurodegeneration.

Bottom line — reducing the possibility of developing diabetes markedly reduces your chances of developing Alzheimer’s disease. Diabetes begins with prediabetes, so the place to start your preventive work is there.

Prediabetes

115 million Americans have prediabetes. 81% do not know it. 18% of teens have prediabetes, and this number is on the rise.

The typical person with prediabetes is overweight, has excess belly fat, and is sedentary. They tend to eat a diet high in sugar and foods that are quickly digested into sugar, as well as ultra-processed foods. Many will also have a family history of diabetes.

Those with prediabetes have a 5–10% chance of progressing to diabetes each year, which accumulates so that in 3–5 years, 15–30% will have developed diabetes. And, if followed for enough years, up to 70% will progress.

Prediabetes is diagnosed by measuring your average blood glucose over the course of 2 to 3 months. This is done with a test called A1c, a blood test that can be drawn at any time of day. If the A1c is between 5.7% and 6.4%, that is diagnostic of prediabetes. If it’s 6.5% or higher, that’s diagnostic of diabetes. As noted, most people with prediabetes don’t know it. However, the A1c test is simple and inexpensive. If you have any of the risk factors for prediabetes, it’s well worth your while to have the test. Your doctor may order it at your annual evaluation. Ask to have it done and then ask for the result.

Knowing you have prediabetes is essential because the progression to diabetes can be reversed with lifestyle changes. Yes, these can be challenging, but they are well worth the time and effort so that you do not progress to diabetes and all of its downstream complications, including dementia.

The other reason to reverse prediabetes is that it is not a benign condition. It is silent but causes trouble over time. Prediabetes leads to slow but long-term damage to blood vessels, the heart, and the kidneys. Prediabetes can be part of the metabolic syndrome — a combination of any three of elevated blood sugar, high blood pressure, high LDL cholesterol and low HDL cholesterol, elevated triglycerides, and excess belly fat. These conditions in combination lead to diabetes, heart disease, stroke, fatty liver disease, and cognitive decline.

Although usually not measured, the underlying problem is the early stages of insulin resistance when the pancreas can still compensate by producing excessive insulin to overcome the resistance. Once it can no longer do that, blood glucose remains high, and you now have diabetes.

Reversing prediabetes

The good news is that you can reverse prediabetes back to normal. The steps are straightforward and usually do not require medication. Since prediabetes develops because of being overweight, being sedentary, and eating too much sugar and foods that readily convert to sugar, the steps are straightforward.

Check your waist-to-height ratio. Your waist should be less than 50% of your height. Details here.

Losing just 5 to 7% of body weight will reduce the risk of progressing to diabetes by 50%. For a 200-pound person, this is only 10–14 pounds. The second step is to get about 150 minutes of aerobic exercise each week. A brisk 30-minute walk five days a week will suffice. Add resistance exercises 2 to 3 times per week.

The third step is to eat a low-glycemic (meaning food that does not digest to sugar rapidly and thereby leads to rapid increases in blood sugar — think candy, ice cream, cakes), micronutrient-dense diet that includes increased fiber intake, non-starchy vegetables (for example, dark green veggies), whole grains (whole wheat, brown rice), legumes (beans and lentils), lean meats, fish, eggs, nuts, and avocados.

It is very important to reduce sugary drinks and high-sugar foods, such as pastries, pies, and ice cream. Eating only whole grains means no products made from white flour, such as white bread, most prepared cereals, pastries, and donuts.

Avoid ultra-processed foods, as they contain high levels of sugar, salt, and white flour. Ultra-processed foods themselves are linked to dementia. It is also important to get adequate sleep and to reduce chronic stress.

It’s a good idea to monitor your progress with continuous glucose monitoring. It will show you whether certain foods cause spikes in blood sugar and how exercise affects it. These monitors are now available at most pharmacies.

These lifestyle changes can reverse prediabetes within a few months.

You want to get your A1c level down, not just to the upper limit of normal at 5.6, but lower still, because the cutoff from normal to prediabetes, although highly useful, is still a static number. You want to be well under the top limit of “normal.”

Some people have tried but cannot lose weight or can’t keep it down after losing. They often benefit from using a GLP1 drug such as Wegovy (semaglutide) and Zepbound (tirzepatide). For many people, these have proven highly valuable. A word of caution. Weight loss usually includes both fat and muscle, so you need to do resistance exercises to counteract muscle loss. Once started, many people need to continue indefinitely, otherwise they regain weight, fat, but not muscle.

It is to your definite advantage to learn if you have prediabetes and then to do what is needed to reverse it. Habits can be difficult to modify, but the benefits are so great that the time and effort are well worth it, including a major risk reduction in dementia. And remember, it is never too late to get started.

With thanks to retired long-time expert diabetes educator Charlene Freeman, RN CDE CPT

The post Diabetes Is a Major Risk Factor for Dementia. 115 Million Americans Have Prediabetes. appeared first on Medika Life.

In later life, weight loss can be a double‑edged sword. A few pounds off the joints can be both helpful and risky. Shedding a few pounds may ease joint pain, but losing weight without meaning to can be a warning sign. Fast weight loss can also lead to muscle loss, which is key to staying independent.

Experts also point out practical issues: injections need good vision, steady hands, and a regular routine. Stomach and bowel side effects can be tougher for seniors, especially if they’re already losing weight without trying. complicate life for older adults — and how to approach them with a “safety first” mindset.

1) Aging changes the risk–benefit math (even when a drug “works”)

Older adults, especially those who are frail or have several health issues, are often left out of clinical trials. This is important because average trial results may not match the real-life experience of a 75-year-old who takes several medications and needs to manage appetite and hydration.

A 2024 debate paper on GLP-1 drugs in older patients, including those with kidney disease, points out that limited trial data and multiple medications make it harder to judge safety and effectiveness for frailer seniors. Clinicians need to make decisions based on each person, not just on averages. In simple terms, the real question is not whether GLP-1s are good or bad, but whether they help this specific older person with their unique health needs.

There’s another subtle issue: in later life, the goal is often less about chasing an ideal weight and more about protecting function—walking safely, rising from a chair, maintaining balance, staying hydrated, and maintaining enough strength to live independently. So for older adults, the most important question isn’t “How much weight will I lose?” It’s “What will this do to my strength, my nutrition, and my ability to stay steady on my feet?”

2) Common side effects can become serious for older adults.

GLP-1s often cause nausea, vomiting, diarrhea, constipation, and less appetite. Younger people may find these symptoms unpleasant but manageable. For older adults, though, these issues can quickly lead to dehydration, dizziness, and falls, especially if they also take blood pressure medicines or diuretics.

Current FDA labeling for semaglutide products highlights this pathway: stomach and bowel side effects can lead to volume depletion, and acute kidney injury has occurred, including in postmarketing reports. The label advises monitoring kidney function when starting or increasing doses in people who develop severe gastrointestinal reactions, and it notes that dehydration has been part of reported kidney injury cases.

This is how many real-life problems start: a few days of not being able to eat or drink much, then feeling lightheaded, falling, or needing emergency care for dehydration. Older adults may not feel as thirsty and may have less ability to recover. So, it’s important to watch hydration, electrolytes, blood pressure, and kidney function, especially in the first months of treatment and after increasing the dose.

3) Muscle and frailty: losing weight does not always mean better health.

The headline benefits of GLP‑1s often focus on pounds lost. But the body doesn’t lose only fat. Lean mass (including muscle) can drop, too. This matters in older adults because age‑related muscle loss (sarcopenia) is already common — and it’s tightly linked to frailty, falls, and loss of independence.

A 2025 mini-review on older adults warns that starting and stopping GLP-1s repeatedly can change body composition, sometimes leading to ‘sarcopenic obesity’ — having too much fat and too little muscle. The authors are not saying to avoid GLP-1s, but to remember that weight loss does not always mean better health for older people.

More pointedly, a 24‑month retrospective cohort study in older adults with type 2 diabetes reported that semaglutide use was associated with muscle loss and functional decline, particularly at higher doses and in patients who already had sarcopenia. The authors emphasize individualized risk–benefit assessment and the need for monitoring and intervention.

If you’re reading this as an older adult, it may help to translate the research into plain questions to bring to your next appointment: “If I lose weight, how will we protect my muscles?” “How will we check whether I’m getting weaker?” “What would make us stop or change course?” An older adult who becomes “smaller but weaker” has not gained health — only risk.

4) Other complications: gallbladder, pancreas, vision, and low blood sugar

Gallbladder and bile duct problems can be an unexpected issue. Losing weight already increases the risk of gallstones, and GLP-1s seem to increase it even further. A large review found that using GLP-1 drugs increases the chance of gallbladder or bile duct disease, especially at higher doses, for longer periods, or when used for weight loss.

For older adults, this might present as sudden pain in the upper right side of the belly, nausea, fever, or pain spreading to the back or shoulder. These symptoms should be checked by a physician right away.

GLP-1 drug labels also warn about the risk of sudden pancreatitis and say to get medical help for severe, ongoing belly pain. The overall risk is low, but older adults may have additional risk factors, such as gallstones or high triglycerides. Severe belly pain in later life should always be checked quickly.

Then there’s the risk of blood sugar dropping too low. GLP‑1s don’t usually cause hypoglycemia by themselves, but the risk rises when combined with insulin or sulfonylureas. Semaglutide labeling warns that concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia and may require dose reductions of those agents.

In older adults, hypoglycemia can be particularly dangerous: it can cause falls, confusion, fainting, and cardiac stress. It’s also easier to miss, because symptoms may look like “just being tired” or “a little off today,” especially in someone who already has memory or balance problems.

Eyes and vision deserve special attention. Semaglutide labeling includes a warning about diabetic retinopathy complications and recommends monitoring patients with a history of retinopathy. Beyond labeling, post‑marketing safety monitoring continues to explore visual signals.

A 2025 analysis of FDA adverse event reporting data found a potentially elevated risk of vision‑impairment reports with semaglutide use compared with some other diabetes and weight‑loss medications, and it called for vigilant surveillance and further research. That doesn’t prove the drug causes vision loss in an individual patient, but it is enough to justify a cautious posture: new blurring, blind spots, or sudden changes deserve a same‑week medical call, not a “let’s see if it passes.”

5) Surgery and sedation: delayed stomach emptying can cause problems

GLP‑1 medications slow stomach emptying — one reason people feel full sooner. But that same effect can complicate anesthesia and deep sedation if food remains in the stomach despite standard fasting. A 2024 review describes the connection between GLP‑1 medications, delayed gastric emptying (including gastroparesis), and increased risk of aspiration during anesthesia, as well as possible effects on the absorption of other medications.

This issue has become important enough that several medical groups have created guidelines for surgery. The 2024 guidance says many people can continue taking GLP-1s, but doctors should look for higher-risk situations, such as people with stomach problems or other risks of food entering the lungs, and adjust plans as needed.

This is important for older adults because they are more likely to undergo procedures requiring sedation, such as colonoscopies, joint injections, cardiac procedures, dental work, or surgeries. The easiest and most often missed safety step is to tell every physician involved — surgeon, anesthesiologist, endoscopist, dentist — that you are taking a GLP-1 medication and when you last took it. Do not assume it will be clear in your medical chart.

6) A senior‑friendly “yes, with a plan” approach

If you’re an older adult considering a GLP‑1 (or already taking one), a safer approach often looks like “yes, with monitoring.” That means starting with function, not just the scale: tracking energy, steadiness, and strength in everyday life, not only pounds.

It also means treating hydration as a real medical concern. Ongoing nausea, vomiting, or diarrhea is not just part of getting used to the medicine. These symptoms can affect blood pressure and kidney function, especially when changing doses.

Because muscle matters so much in later life, protecting it should be part of the prescription. That can include discussing protein intake, adding a realistic strength plan (even chair‑based work or physical‑therapy guided resistance), and reassessing the medication if weight loss is accompanied by weakness, poor balance, or reduced stamina.

Older adults should also have their medications reviewed with a focus on preventing low blood sugar. If insulin or a sulfonylurea is being used, doses may need to be adjusted as appetite decreases and blood sugar improves.

Finally, it is important to take symptoms seriously. New stomach pain, ongoing vomiting, or sudden vision changes should be checked by a doctor right away. Before any procedure with anesthesia or deep sedation, make sure to tell the medical team about your GLP-1 use — do not assume they already know.

The GLP-1 medications can help some older adults, but there is less room for mistakes. Side effects can quickly lead to dehydration, frailty, falls, or problems during procedures. The safest approach is not just ‘yes’ or ‘no,’ but ‘yes, with a plan’ — one that protects hydration, nutrition, muscle, vision, and safety during medical care.

The post GLP‑1 Medications in Later Life: Why the “Miracle Shot” Needs a Senior‑Specific Safety Lens appeared first on Medika Life.

In later life, weight loss can be a double‑edged sword. A few pounds off the joints can be both helpful and risky. Shedding a few pounds may ease joint pain, but losing weight without meaning to can be a warning sign. Fast weight loss can also lead to muscle loss, which is key to staying independent.

Experts also point out practical issues: injections need good vision, steady hands, and a regular routine. Stomach and bowel side effects can be tougher for seniors, especially if they’re already losing weight without trying. complicate life for older adults — and how to approach them with a “safety first” mindset.

1) Aging changes the risk–benefit math (even when a drug “works”)

Older adults, especially those who are frail or have several health issues, are often left out of clinical trials. This is important because average trial results may not match the real-life experience of a 75-year-old who takes several medications and needs to manage appetite and hydration.

A 2024 debate paper on GLP-1 drugs in older patients, including those with kidney disease, points out that limited trial data and multiple medications make it harder to judge safety and effectiveness for frailer seniors. Clinicians need to make decisions based on each person, not just on averages. In simple terms, the real question is not whether GLP-1s are good or bad, but whether they help this specific older person with their unique health needs.

There’s another subtle issue: in later life, the goal is often less about chasing an ideal weight and more about protecting function—walking safely, rising from a chair, maintaining balance, staying hydrated, and maintaining enough strength to live independently. So for older adults, the most important question isn’t “How much weight will I lose?” It’s “What will this do to my strength, my nutrition, and my ability to stay steady on my feet?”

2) Common side effects can become serious for older adults.

GLP-1s often cause nausea, vomiting, diarrhea, constipation, and less appetite. Younger people may find these symptoms unpleasant but manageable. For older adults, though, these issues can quickly lead to dehydration, dizziness, and falls, especially if they also take blood pressure medicines or diuretics.

Current FDA labeling for semaglutide products highlights this pathway: stomach and bowel side effects can lead to volume depletion, and acute kidney injury has occurred, including in postmarketing reports. The label advises monitoring kidney function when starting or increasing doses in people who develop severe gastrointestinal reactions, and it notes that dehydration has been part of reported kidney injury cases.

This is how many real-life problems start: a few days of not being able to eat or drink much, then feeling lightheaded, falling, or needing emergency care for dehydration. Older adults may not feel as thirsty and may have less ability to recover. So, it’s important to watch hydration, electrolytes, blood pressure, and kidney function, especially in the first months of treatment and after increasing the dose.

3) Muscle and frailty: losing weight does not always mean better health.

The headline benefits of GLP‑1s often focus on pounds lost. But the body doesn’t lose only fat. Lean mass (including muscle) can drop, too. This matters in older adults because age‑related muscle loss (sarcopenia) is already common — and it’s tightly linked to frailty, falls, and loss of independence.

A 2025 mini-review on older adults warns that starting and stopping GLP-1s repeatedly can change body composition, sometimes leading to ‘sarcopenic obesity’ — having too much fat and too little muscle. The authors are not saying to avoid GLP-1s, but to remember that weight loss does not always mean better health for older people.

More pointedly, a 24‑month retrospective cohort study in older adults with type 2 diabetes reported that semaglutide use was associated with muscle loss and functional decline, particularly at higher doses and in patients who already had sarcopenia. The authors emphasize individualized risk–benefit assessment and the need for monitoring and intervention.

If you’re reading this as an older adult, it may help to translate the research into plain questions to bring to your next appointment: “If I lose weight, how will we protect my muscles?” “How will we check whether I’m getting weaker?” “What would make us stop or change course?” An older adult who becomes “smaller but weaker” has not gained health — only risk.

4) Other complications: gallbladder, pancreas, vision, and low blood sugar

Gallbladder and bile duct problems can be an unexpected issue. Losing weight already increases the risk of gallstones, and GLP-1s seem to increase it even further. A large review found that using GLP-1 drugs increases the chance of gallbladder or bile duct disease, especially at higher doses, for longer periods, or when used for weight loss.

For older adults, this might present as sudden pain in the upper right side of the belly, nausea, fever, or pain spreading to the back or shoulder. These symptoms should be checked by a physician right away.

GLP-1 drug labels also warn about the risk of sudden pancreatitis and say to get medical help for severe, ongoing belly pain. The overall risk is low, but older adults may have additional risk factors, such as gallstones or high triglycerides. Severe belly pain in later life should always be checked quickly.

Then there’s the risk of blood sugar dropping too low. GLP‑1s don’t usually cause hypoglycemia by themselves, but the risk rises when combined with insulin or sulfonylureas. Semaglutide labeling warns that concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia and may require dose reductions of those agents.

In older adults, hypoglycemia can be particularly dangerous: it can cause falls, confusion, fainting, and cardiac stress. It’s also easier to miss, because symptoms may look like “just being tired” or “a little off today,” especially in someone who already has memory or balance problems.

Eyes and vision deserve special attention. Semaglutide labeling includes a warning about diabetic retinopathy complications and recommends monitoring patients with a history of retinopathy. Beyond labeling, post‑marketing safety monitoring continues to explore visual signals.

A 2025 analysis of FDA adverse event reporting data found a potentially elevated risk of vision‑impairment reports with semaglutide use compared with some other diabetes and weight‑loss medications, and it called for vigilant surveillance and further research. That doesn’t prove the drug causes vision loss in an individual patient, but it is enough to justify a cautious posture: new blurring, blind spots, or sudden changes deserve a same‑week medical call, not a “let’s see if it passes.”

5) Surgery and sedation: delayed stomach emptying can cause problems

GLP‑1 medications slow stomach emptying — one reason people feel full sooner. But that same effect can complicate anesthesia and deep sedation if food remains in the stomach despite standard fasting. A 2024 review describes the connection between GLP‑1 medications, delayed gastric emptying (including gastroparesis), and increased risk of aspiration during anesthesia, as well as possible effects on the absorption of other medications.

This issue has become important enough that several medical groups have created guidelines for surgery. The 2024 guidance says many people can continue taking GLP-1s, but doctors should look for higher-risk situations, such as people with stomach problems or other risks of food entering the lungs, and adjust plans as needed.

This is important for older adults because they are more likely to undergo procedures requiring sedation, such as colonoscopies, joint injections, cardiac procedures, dental work, or surgeries. The easiest and most often missed safety step is to tell every physician involved — surgeon, anesthesiologist, endoscopist, dentist — that you are taking a GLP-1 medication and when you last took it. Do not assume it will be clear in your medical chart.

6) A senior‑friendly “yes, with a plan” approach

If you’re an older adult considering a GLP‑1 (or already taking one), a safer approach often looks like “yes, with monitoring.” That means starting with function, not just the scale: tracking energy, steadiness, and strength in everyday life, not only pounds.

It also means treating hydration as a real medical concern. Ongoing nausea, vomiting, or diarrhea is not just part of getting used to the medicine. These symptoms can affect blood pressure and kidney function, especially when changing doses.

Because muscle matters so much in later life, protecting it should be part of the prescription. That can include discussing protein intake, adding a realistic strength plan (even chair‑based work or physical‑therapy guided resistance), and reassessing the medication if weight loss is accompanied by weakness, poor balance, or reduced stamina.

Older adults should also have their medications reviewed with a focus on preventing low blood sugar. If insulin or a sulfonylurea is being used, doses may need to be adjusted as appetite decreases and blood sugar improves.

Finally, it is important to take symptoms seriously. New stomach pain, ongoing vomiting, or sudden vision changes should be checked by a doctor right away. Before any procedure with anesthesia or deep sedation, make sure to tell the medical team about your GLP-1 use — do not assume they already know.

The GLP-1 medications can help some older adults, but there is less room for mistakes. Side effects can quickly lead to dehydration, frailty, falls, or problems during procedures. The safest approach is not just ‘yes’ or ‘no,’ but ‘yes, with a plan’ — one that protects hydration, nutrition, muscle, vision, and safety during medical care.

The post GLP‑1 Medications in Later Life: Why the “Miracle Shot” Needs a Senior‑Specific Safety Lens appeared first on Medika Life.

If you’re an adult in the U.S., you can expect to gain 10 to 25 pounds between your 20s and your 40s. Starting between ages 30 and 40, you may find losing weight and exercising more challenging. The exercise you do may not have the same effect as before. It’s not necessarily a sign that something is wrong. This weight gain in middle age—known as “middle-age spread”—is a natural consequence of aging.

“Your metabolism tends to slow down as you get older,” says NIH’s Dr. Rafael de Cabo, an expert on aging. “But your appetite and your food intake do not. So, you have a steady increase of body weight with age.”

Much of the weight gain comes in the form of fat tissue. The distribution of fat in your body also shifts. There’s less under your skin and more around your internal organs. Meanwhile, you start to lose lean muscle with age. Many people also become less active as they age, especially if they have a job that involves a lot of sitting. This can lead to further fat gain and muscle loss.

Those extra pounds have consequences beyond your clothes not fitting. The risk of many chronic diseases, such as diabetes, heart disease, and neurodegenerative diseases, goes up with age. Excess weight can further heighten these risks.

Fortunately, you can take steps to maintain a healthy weight as you age. Your diet can play a key role. Having a slower metabolism means you’ll need fewer calories. But you also want to make sure you still get all the nutrients your body needs. Get tips on healthy eating as you age.

De Cabo studies the effects of dietary changes on health and longevity. One example is intermittent fasting, in which meals are interspersed with long fasting periods. For example, you might limit eating to only eight hours per day. Studies suggest intermittent fasting may help some people to eat less and keep weight off. But De Cabo and others have been finding that it might also have benefits for your metabolism.

His work has shown that mice live longer and stay healthier when they go for long periods between meals. This was true even if they were eating the same amounts and types of foods as mice that ate whenever they wanted. Other studies have also suggested that periods of fasting may bring benefits beyond weight loss.

Physical activity is important for combating the changes that come with aging, too.

“The key is to maintain an active lifestyle,” de Cabo says. “Try to incorporate daily walks or daily visits to the gym. If you have an office job, get a standup desk, so you spend a few hours a day standing instead of sitting. Small doses of exercise throughout the day will help tremendously.”

Visit: https://newsinhealth.nih.gov/2024/10/stopping-middle-age-spread for more information.

The post Stopping Middle-Age Spread appeared first on Medika Life.

I was standing in my kitchen at 1:07 a.m., the only illumination a cold rectangle from the refrigerator.

It felt like a reversed Caravaggio scene. Darkness everywhere, a harsh pool of light on a plate of leftovers.

I was not hungry.

The light wired me awake. It felt like an invitation to eat.

I am a radiation oncologist.

I discuss circadian clocks with patients more often than most in my specialty because I’ve seen, over decades, how sleep, light, food timing, stress, and movement influence recovery, inflammation, and weight.

When you sit in a treatment room for a long enough time, you start to notice patterns.

People who live in bright evenings and dim mornings often struggle with appetite, cravings, and maintaining a healthy body composition.

They are swimming upstream against their biology.

This is the essay I wish someone had handed me ten years ago.

Light is not neutral.

It is a metabolic signal.

And the way we dose it each day can quietly nudge our insulin, our melatonin, our leptin and ghrelin, our brown fat, and even the clocks inside our liver and pancreas.

Let me show you how to use that to your advantage.

The Night I Realized Light Exposure Could Make You Fat.

In the clinic, I began asking a new question: not just how many hours you sleep, but how much light hits your eyes after sunset.

Most patients stared. Then came the stories: three glowing screens, bright LEDs in the bedroom, a dog walk under sodium street lamps.

Late light. Fragmented sleep.

Late eating. Creeping weight.

Our fat cells tell time. So do our mitochondria. So does your gut microbiome.

Light at the wrong time scrambles those clocks. Scrambled clocks change how you store energy.

Your Fat Has a Clock: Circadian Rhythm, Metabolism, and Weight Gain.

Every cell in your body keeps time.

Morning light anchors the master clock in your brain, which in turn syncs the clocks in your organs and fat cells.

Weak morning light and strong evening light throw those clocks out of phase.

The result is a subtle metabolic jet lag that never ends.

Quiet jet lag doesn’t show up on your calendar. It shows up on your scale.

Melatonin, insulin, and the late-night snack

Melatonin is not just a sleep hormone.

It cross-talks with insulin.

When melatonin levels are high, your ability to handle glucose decreases.

That is adaptive if you are asleep.

It is not adaptive if you are scrolling with a bowl of cereal near midnight.

Bright light at night suppresses melatonin, delays sleep, and shifts appetite later.

You wake underslept, with more ghrelin, less leptin, and a stronger drive to eat ultraprocessed food.

Rinse. Repeat.

Want to reset your metabolism?
→ Get my Micro-Habits bundle for daily light protocols, circadian checklists, and the exact scripts I give patients.

Morning light is metabolic medicine.

Ten minutes of unfiltered outdoor light soon after waking can move your circadian clock earlier, deepen your sleep that night, and improve next-day insulin sensitivity.

Morning light is rich in wavelengths your brain needs to set the day. Indoors, even bright-looking rooms are often one or two orders of magnitude dimmer than outside.

Your brain can tell the difference. So can your pancreas.

If you do one thing after reading this, step outside within 30 minutes of waking.

If it is cloudy, go anyway. If it is winter, aim longer. Treat it as you would a prescription.

Darkness is a habit

We talk about sleep hygiene.

We rarely talk about darkness hygiene.

Your retina is exquisitely sensitive to blue light, but even dim bulbs can disrupt your sleep cycle.

Swap bedside LEDs for warm, low-lux bulbs.

Set your phone to grayscale and enable a screen sunset. Cover the power lights with black tape.

Close the fridge quickly. Dim your home two hours before bed until it resembles a Rembrandt painting.

Your metabolism prefers Rembrandt over Times Square.

What I tell patients in the clinic

1. See the morning light early and consistently.
2. Eat most of your calories in the daylight zone.
3. Dim the house two hours before you want to sleep.
4. Stop eating at least two to three hours before going to bed.
5. Keep the bedroom dark, cool, and free of screens.
6. Anchor wake time seven days a week.
7. Move your body in the day, not at midnight.
8. Treat shift work like altitude. You need extra recovery, extra discipline, and a plan.

Micro-habits that fix your light diet

• Lux-before-latte rule: no coffee until you have been outside.
• Two-switch protocol: one button that turns off all bright overheads at 8 p.m., one that turns on warm lamps. Make darkness effortless.
• Yellow-card your phone: night shift mode, grayscale, and a screen curfew you respect.
• Front-load protein: bigger breakfast and lunch, smaller dinner. Your insulin sensitivity is higher earlier.
• Walk after dinner: even ten minutes blunts the glucose spike and helps your clock wind down.
• Bedroom audit: cover LEDs, use blackout curtains, move chargers to the hallway.
• Weekend consistency: Social jet lag is a form of metabolic jet lag. Keep your wake time within 60 minutes of weekdays.

The lab evidence in plain English

Animal models demonstrate that mistimed light exposure leads to weight gain, even without consuming extra calories.

Human studies have linked nighttime light exposure to a higher BMI, poorer sleep, and worse glucose control.

Shift workers have higher risks of obesity, diabetes, and some cancers.

These conditions are not destiny. They are signals you can change.

If you still want numbers

Chronobiology papers repeatedly show that eating the same calories at night causes a higher postprandial glucose and insulin response than eating them in the morning.

Timed light therapy can correct delayed sleep phase and improve metabolic markers.

Dim light at night correlates with higher rates of depression and weight gain.

Again, correlation is not causation, but the mechanisms are biologically sound.

A one-week protocol to test on yourself

Day 1 to 2

• Wake at the same time both days.
• Get 15 minutes of outdoor light within 30 minutes of waking.
• Track meals. Eat 80 percent of calories by 4 p.m.
• Dim the house lights at 8 p.m. Aim for minimal screen time.
• Sleep in full darkness.

Day 3 to 7

• Extend morning light to 20 minutes.
• Add a 10-minute post-dinner walk.
• Keep dinner smallest and earliest.
• Keep wake time strict.
• Note morning hunger and energy. By day 4, many people report fewer nighttime cravings.

How this plays out in the real world

A patient with breast cancer told me she could not lose weight despite “doing everything right.”

She tracked calories, lifted weights, and avoided ultraprocessed foods. She also answered emails at midnight under bright LED downlights and ate a second dinner at 10:30 p.m.

We moved her dinner to 6 p.m., instituted a house-wide dim at 8 p.m., added morning light exposure, and asked her to maintain a stable wake time, even on weekends.

Six weeks later, she had lost six pounds without changing her total calorie intake.

Her sleep improved. Her cravings diminished.

The scale finally listened.

The broader stakes of light exposure and weight gain

We are the first species to flood the night with light and the day with dimness.

We built a 24-hour culture and then wondered why our biology pushed back.

Weight gain is not a character flaw.

It is often a circadian mismatch.

Fix the light. Observe the effects on hunger, sleep depth, glycemic control, and weight.

Final Thoughts

Light is a drug.

Dose it wisely.

Morning heals.

Evening disrupts.

Darkness is a habit, not a switch.

If your weight has been creeping up, remember this: your first diet is not on your plate.

It is in your eyes.

→ Want my full circadian reset, daily checklists, and Micro-Habits plan? Get the Micro-Habits bundle today.

→ Follow me here on Medium for more science-backed, story-driven guides to living longer and better.

Author bio: I am a radiation oncologist who writes daily about longevity, cancer prevention, and the small habits that change health trajectories.

The post The Strange Link Between Light Exposure and Weight Gain appeared first on Medika Life.

Many of us may take multiple medications daily, and we depend on our prescriber’s ability to monitor those that are safe for us and exclude those that may be problematic. Anyone who wishes to be safer may do a bit of their research, and that’s fine. It does not mean you are suspicious; you only wish to ensure there’s no problem.

Hundreds of medications are listed, and it’s almost impossible for anyone to know if a medication could cause one of those rare effects for you. It is, therefore, in your best interest to be vigilant for these effects. In addition to being aware of the side effects, most patients would not know that the number of side effects may increase as the number of people taking the medication increases. Not every side effect manifests immediately, and it may require a significant increase in medication usage for it to show up.

How does a side effect enter the PDR? Usually, during clinical trials where drugs are being tested on patients, the principal investigator (PI) and those involved at the clinical sites will note any side effects that subjects report. Occasionally, an ultra-concerned clinical investigator may turn up a problem that isn’t one.

I recall a woman who developed a rash during clinical trials of a medication. Later, researchers determined that her caregiver had caused the rash by applying skin cream to her. The rash, however, continued to appear as a side effect of the drug. Although the rash wasn’t severe wasn’t related to the medication, it suggested that the researcher was very cautious about their protocol records.

Over the past several years, the discovery and prescribing of weight loss drugs (usually GLP-1) have been noted to have some mild side effects, and several studies have indicated what to expect in terms of side effects. Gut bacterial action causes bad breath (Ozempic breath), but it was easily manageable, provided the healthcare prescriber also examined any dental problems.

The Potential Risks

In another study, semaglutide was associated with a prevalence of nausea (44.10%), vomiting (24.58%), and gastroesophageal reflux disease (GERD) (6.28%) in obese individuals.

However, researchers are now expressing additional concerns about side effects that have emerged after tens of thousands of people have used these medications. How do these drugs work, and what are they noting?

By stimulating the body to create more insulin, these drugs decrease blood sugar levels. They also slow food’s passage through the stomach and lessen the sugar released into the bloodstream. When the digestive process is delayed, patients experience prolonged feelings of fullness, which can reduce their caloric intake and lead to weight loss. The action of the drugs would seem beneficial, especially for those who need to control their blood sugar levels and their weight.

But there was an increased risk, however, of gastrointestinal disorders, hypotension, syncope, arthritic disorders, nephrolithiasis, and interstitial nephritis associated with GLP-1RA use compared to usual care.

Researchers also followed more than 200,000 diabetics taking GLP-1 meds and over 1.7 million diabetics using other medications to decrease blood sugar for around 3.5 years. The study did find that using GLP-1 was not without its hazards. They found these medications were associated with an increased risk of pancreatitis of 146% and an increased risk of arthritis of 11%. But most of the study’s participants were white men in their 60s and 70s with US VA ties. Such a sample would not necessarily provide the most robust results, and future studies need to be much more diverse in the population studied.

The Vanity Factor

Aside from any physical effects, there is also something women especially might be concerned about: Ozempic face. A New York dermatologist came up with this term. It means that losing weight can make your face look older because of the tissue that is being lost. The fact that videos describing it have received millions of views indicates the extent of concern.

But when it comes to treating type 2 diabetes, the GLP-1 RA family provides positive benefits. In addition to a favorable impact on weight and a low risk of hypoglycemia, all medicines in the class have shown substantial reductions in A1C.

Despite some noted adverse side effects, the medications have proven beneficial to a significant number of users. However, as with everything, the benefits and risks must be weighed carefully, and Ozempic face should not be a negative when considering questions of health.

The post Skinnier, Sicker? Weight-Loss Meds Raise Concerns appeared first on Medika Life.

However, it was only recently that I began targeting something deeper.

Something upstream.

Something ancient.

Inflammation.

Not the helpful kind you get after a cut or cold. That kind heals.

I’m talking about chronic inflammation — the kind that lingers quietly, damaging your blood vessels, brain, joints, and organs like a slow, internal wildfire.

Over time, I’ve come to believe that chronic inflammation is the common thread behind most chronic diseases. The evidence keeps stacking up.

The Number That Predicts How Fast You’re Aging

Most doctors ignore it. I don’t.

medium.com

The Hidden Fire Behind Disease

Dementia? Check.

Type 2 diabetes? Check.

Heart attacks. Strokes. Obesity. Cancer?

Check, check, check.

We call these conditions separate diagnoses.

But I’ve come to see them as symptoms of a deeper cause: the body’s immune system stuck in the “on” position.

Scientists have even coined a term: inflammaging — the chronic, low-grade inflammation that accelerates aging and shortens lifespan.

That realization changed the way I live.

6 Ways I’m Extinguishing the Fire

I don’t believe in silver bullets. But I do believe in stacking small daily wins. Here’s how I’m pushing back against chronic inflammation:

1. Sleep Like It’s Medicine

Sleep isn’t optional. It’s therapeutic.
Insufficient sleep increases inflammatory markers, such as C-reactive protein. But quality sleep can lower them, especially when it becomes a consistent, protected ritual.

I now aim for 7.5–8 hours per night, without apology. I treat it like an appointment; I don’t cancel.

2. Move Daily, Not Occasionally

Exercise cools inflammation, especially the aerobic kind.
Walking. Cycling. Swimming. Even light strength training. They all lower pro-inflammatory cytokines and boost your cellular resilience.
And yes, I consider walking to be medicine.

3. Eat Food That Fights for You

I’ve shifted toward a Mediterranean-style diet, which includes olive oil, vegetables, nuts, berries, and fatty fish.
I’ve also added turmeric, green tea, and fiber-rich legumes.
These foods don’t just fuel me. They protect me from the inside out.

4. Avoid the Fire-Starters

Two habits pour gasoline on inflammation:

• Smoking
• Excess alcohol

I’ve never smoked. But I do drink on occasion — and now I limit that to one glass a week, if that. Most of the time, sparkling water does the trick just fine.

5. Stay Lean for the Right Reason

Weight isn’t just cosmetic — it’s biochemical.

Visceral fat (the kind that wraps around your organs) fuels inflammation and increases risk for cancer, dementia, and heart disease.

I stay lean, not for a mirror, but for my mitochondria.

6. Take Oral Health Seriously

Inflamed gums = inflamed body.

I didn’t always take flossing seriously. But the link between periodontal disease and heart disease — even cognitive decline — is real.

Now I treat my toothbrush like a prescription.

We Can’t Stop Time — But We Can Stop the Fire

Aging is inevitable.

But how do we age?

That’s far more flexible than most people realize.

If you want more energy, sharper cognition, and a lower risk of disease, start by cooling the flame of inflammation.

It’s not glamorous. But it works.

Final Thoughts

I used to think aging was just a number. Now I think it’s a pattern.

A pattern of how we sleep. How do we move? How do we eat?

And how we treat the quiet signals our body sends us — before they become sirens.

You don’t need a prescription to start.

You just need to start.

If you’re interested in aging better, you might also enjoy This One Lab Result Predicts How Long You’ll Live.

Ready to fight inflammation? Download my free ebook here.
📘 Debunked: 7 Health Myths That Quietly Hurt You
You’ll learn the truth about common habits that silently fuel inflammation, disease, and aging — and how to reverse them.

Author bio:
Michael Hunter, MD, is a cancer doctor, writer, and wellness advocate who believes the best medicine often starts outside the hospital walls.

The post How Chronic Inflammation Accelerates Aging — And 6 Ways to Slow It Down appeared first on Medika Life.

A new independent analysis conducted by actuarial firm Milliman reveals that FlyteHealth’s AI-enabled Comprehensive Obesity Care program, piloted in partnership with the State of Connecticut, yielded both high medication adherence and meaningful short-term cost avoidance within its first year.

A Real-World Test: Public Sector, Private Innovation

Faced with surging costs tied to GLP-1 coverage since 2020, Connecticut’s self-insured employee health plan took a bold step in 2023 by launching a pilot with FlyteHealth to better manage obesity treatment for eligible employees and retirees. The results: a projected $1.2 million in pharmaceutical cost avoidance and an 86% adherence rate among new GLP-1 users—figures that far surpass national benchmarks.

In typical commercial settings, just 32% of patients remain on GLP-1 therapy after one year. Worse, only 27% follow their prescribed dosing schedules. These statistics often lead payers to pull back on coverage. But FlyteHealth’s personalized, tech-enabled approach may offer a path forward that makes medical and fiscal sense.

Clinical Expertise Meets AI-Driven Personalization

FlyteHealth’s model blends decades of clinical experience with data intelligence. The care program is rooted in the methodology of obesity medicine expert Dr. Louis Aronne and powered by a patent-pending AI engine that tailors care plans based on individual biometric and behavioral data.

Patients receive virtual care from a multidisciplinary team—physicians, nurse practitioners, and dietitians—alongside medication management, lifestyle coaching, and digital support via wearables and connected devices.

The program’s precision prescribing approach uses BMI-based triage to match patients with the most appropriate treatments, reserving higher-cost medications for those with more severe obesity.

State Leaders Applaud Value-Driven Innovation

“This partnership with FlyteHealth is a clear example of how forward thinking, evidence-based innovation can improve people’s lives while also protecting taxpayer dollars,” said Connecticut State Comptroller Sean Scanlon. “The results show we can deliver high-quality care that’s both clinically effective and fiscally responsible.”

Cheryl Pegus, MD, MPH, FlyteHealth’s executive board chair, echoed that sentiment: “Employers and payers are rightly concerned about costs and access. FlyteHealth is committed to supporting those goals with proven, cost-effective solutions.”

Beyond Cost: Patient Outcomes and Long-Term Potential

While the Milliman study focused solely on pharmaceutical spending, FlyteHealth reports additional health improvements among participants, including:

• A 7.2% reduction in elevated HbA1c
• A 9.4% drop in blood glucose levels
• 13%–16% average weight loss over 12 months

The clinical team also addressed comorbidities such as sleep apnea, steatohepatitis, and cardiovascular disease—highlighting the comprehensive nature of the program.

FlyteHealth CEO Sloan Saunders emphasized that these results demonstrate more than momentary success: “Milliman’s independent analysis validates our model’s ability to achieve patient adherence, optimize resource use, and create meaningful savings. But this is just the start—we’re focused on long-term health and economic impacts.”

Looking Ahead

FlyteHealth plans to evaluate broader medical cost offsets and total cost-of-care reductions in future studies. As demand grows for solutions that bridge innovation with fiscal responsibility, the Connecticut pilot could serve as a national model for scalable, AI-informed obesity and cardiometabolic care.

To access the full Milliman report or learn more, visit www.flytehealth.com.

The post AI-Powered Obesity Care: FlyteHealth Delivers Big Wins for Connecticut’s Public Employees appeared first on Medika Life.

Q&A

Gil Bashe: You called Converge\OIST the “very first gathering.” Why did Okinawa feel like the right birthplace?

Yasushi Yamamoto: Yes, this is the very first gathering, and we named it Converge\OIST because I’m a big fan of ‘OIST’—the context of the birth, this location, these people. It was the right place and people, a great gathering, and a pleasure to meet old friends in such a beautiful, inspiring place.

Gil Bashe: Your career bridges Tokyo boardrooms and Jerusalem start-ups. Where did your obsession with “convergence” begin?

Yasushi Yamamoto: Innovation cannot be done in an isolated form; it should be done in collaboration with various fields. Professionals with beautiful résumés in Tokyo surround me, but many lack a broader vision. They are so good at something particular, yet it’s a pity they’re busy in silos. I saw the lack of collaboration and started my business, raising money from Japanese corporations for Israeli start-ups. That contrast—dinosaurs with big systems but little ‘challenging spirit’ versus entrepreneurs who ‘run and fix’—motivated me to build synergy between powerful pieces.

Gil Bashe: Modern medicine seems to multiply silos every year. How do you see convergence breaking that pattern?

Yasushi Yamamoto: Medicine has become hyper-specialized. We have gastroenterologists who only look at the upper esophagus or the colon, cardiologists in electrophysiology, and neurologists focused on one nerve pathway. They perfect an art, but they have blinders. Convergence is breaking down those walls.

Gil Bashe: Inviting violinists and AI ethicists to the same podium can feel radical. How did people react when you pitched this mix?

Yasushi Yamamoto: People would never believe me if I hadn’t done serious work in the previous decade. Thanks to that track record, we built trust. Gathering in Okinawa sounded out of context for many professionals, but it wasn’t curiosity but trust that made them come.

Gil Bashe: Every July, you disappear into Kyoto’s 1,200-year-old Gion festival to play the traditional Japanese flute. What does a month of music teach a CEO?

Yasushi Yamamoto: Back home, I’m participating and serving. When I set up my company, I realized it would never be greater than this festival. The experience makes me humble. I received a baton from previous generations and must pass it on to the next. After that month, I ask, ‘Two generations later, how will young people judge the work I’m doing now?’

Gil Bashe: You’ve spoken of building on three “wheels”: science, art, and philosophy. Where is Corundum on that journey?

Yasushi Yamamoto: We started in hardcore science and investment, then gradually expanded to art—like Leonardo da Vinci, artist and scientist in one person. In the coming three to five years, I will put the vehicle of philosophy on top. Combining great minds and spirit, we can create something AI alone cannot deliver.

Gil Bashe: What tangible outcomes do you want from Converge?

Yasushi Yamamoto: First, I want to support OIST, an institution I love. We held the first event there; followed by South by Southwest London. I want more gatherings in multiple locations, bringing talented people with good hearts.

Gil Bashe: You’ve set up subsidiaries for neuroscience, virtual mixed human-data AI, and the microbiome. Why those intersections?

Yasushi Yamamoto: Think of the gut–brain axis. Discovery comes from interaction: AI power, system biology, and the microbiome. Add the element of art to inspire other curious, intelligent people, and the community expands.

Gil Bashe: Food as medicine used to be folk wisdom; you’re turning it into data science. How?

Yasushi Yamamoto: We invested in a project from the Weizmann Institute—the deepest phenotype cohort, hundreds of people over 20 years with genes, metabolites, behavior, nutrition. We link ancient wisdom to ultra-modern science by layering AI on that dataset. We are converging the past, the future, and current ways of life.

Gil Bashe: Philosophy sounds noble, but ventures need cash. How do you square capital with conscience?

Yasushi Yamamoto: I strongly believe in setting vision on a solid philosophical idea, but also in the power of capital. Our job is to propose a hypothesis, bring capital, deploy people, and prove the hypothesis with action. So, we’re raising our next venture fund while creating the Corundum Convergence Institute, a U.S. 501(c)(3), as an alternative financing model to advance science.

CLOSING THOUGHTS

Yamamoto-san reframes the entrepreneur’s impossible triangle—mission, money, and meaning—into an orchestral score. Science provides the bass line, art supplies melody, philosophy sets tempo, and well-deployed capital funds the concert hall. As Converge expands from Okinawa to London and beyond, its founder is betting that harmony, not hierarchy, will unlock the next era of precision health.

The takeaway is disarmingly simple for the rest of us: when great minds tune their instruments to work in harmony, the walls separating our disciplines start to fall—and patients everywhere will hear the music of life-sustaining innovation.

According to Gil Granot Mayer, Executive Vice President, Technology Development & Innovation at OIST:

“In just two days, we managed to connect people from different disciplines and geographies, immersing them in the OIST spirit and Okinawa’s culture. From understanding the value of the long tail to different approaches to improving life through the Human Phenotype Project, or the understanding of a new aging mechanism associated with cell membrane damage. I hope that these new connections and cutting-edge talks will spark new collaborations and great results.”

The post Blending Renaissance Thinking and Collaborative Power to Address Global Health Challenges appeared first on Medika Life.